Comparison · NCT01020019-5ec62e4a
Lofexidine and Dronabinol vs Placebo: 21 Days of Consecutive Abstinence as Measured by the Time-line Followback.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Lofexidine and Dronabinol vs Placebo: 21 Days of Consecutive Abstinence as Measured by the Time-line Followback. Trial comparisons, record NCT01020019-5ec62e4a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01020019-5ec62e4a
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.279 | 0.182 | 0.402 | wilson | |
| Risk in group 2 | 0.295 | 0.196 | 0.419 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0164 | -0.174 | 0.142 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.944 | 0.54 | 1.65 | log | |
| Odds ratio, group 1 over group 2 | 0.923 | 0.421 | 2.02 | log | |
| Number needed to treat, for one fewer participant with the outcome on Lofexidine and Dronabinol than on Placebo | 61 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Lofexidine and Dronabinol | Maintained at 1.8mg/day Lofex. and 60 mg/day of Dronabinol~Lofexidine and Dronabinol: Lofex: .6 mg/ TID Dronabinol: 20 mg/TID | 17 | 61 | OG001 |
| Group 2 | Placebo | Lofex. matched placebo Dronabinol placebo~Placebo: Placebo control | 18 | 61 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- 21 Days of Consecutive Abstinence as Measured by the Time-line Followback.
- Description
- Time frame
- reported daily for 12 weeks/ or study participation
- Population
Source ClinicalTrials.gov
Trial
- Title
- Combined Pharmacotherapy for Cannabis Dependency
- NCT number
- NCT01020019
- Phases
- PHASE2, PHASE3
- Conditions
- Cannabis Dependence, Marijuana Dependence
- Interventions
- Dronabinol, Placebo, Lofexidine
- Lead sponsor
- New York State Psychiatric Institute
- Results first posted
- 2016-05-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01020019?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01020019-5ec62e4a